Axsome Therapeutics
(NASDAQ:AXSM)
$73.43
-0.78[-1.05%]
At close: May 31
$73.43
0[0.00%]
After Hours: 5:04PM EDT
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$190.00
Lowest Price Target1
$49.00
Consensus Price Target1
$111.68

Axsome Therapeutics Stock (NASDAQ:AXSM), Analyst Ratings, Price Targets, Predictions

Axsome Therapeutics Inc has a consensus price target of $111.68, established from looking at the 90 latest analyst ratings. The last 3 analyst ratings were released from Mizuho, Citigroup, and Baird on May 8, 2024, May 7, 2024, and May 7, 2024. With an average price target of $114.33 between Mizuho, Citigroup, and Baird, there's an implied 55.70% upside for Axsome Therapeutics Inc from these 3 analyst ratings.

Analyst Trend
7
Feb
8
Mar
3
Apr
4
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Mizuho
Citigroup
Baird
HC Wainwright & Co.
Morgan Stanley

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Axsome Therapeutics

Buy NowGet Alert
05/08/2024Buy Now44.36%Mizuho
Graig Suvannavejh
$109 → $106MaintainsBuyGet Alert
05/07/2024Buy Now70.23%Citigroup
David Hoang
$127 → $125MaintainsBuyGet Alert
05/07/2024Buy Now52.53%Baird
Joel Beatty
$108 → $112MaintainsOutperformGet Alert
05/07/2024Buy Now158.75%HC Wainwright & Co.
Raghuram Selvaraju
 → $190ReiteratesBuy → BuyGet Alert
04/29/2024Buy Now56.61%Morgan Stanley
Vikram Purohit
$90 → $115UpgradeEqual-Weight → OverweightGet Alert
04/10/2024Buy Now45.72%Cantor Fitzgerald
Charles Duncan
 → $107ReiteratesOverweight → OverweightGet Alert
04/02/2024Buy Now158.75%HC Wainwright & Co.
Raghuram Selvaraju
$190 → $190MaintainsBuyGet Alert
03/28/2024Buy Now48.44%Mizuho
Graig Suvannavejh
$108 → $109MaintainsBuyGet Alert
03/26/2024Buy Now104.28%Truist Securities
Joon Lee
 → $150MaintainsBuyGet Alert
03/26/2024Buy Now74.32%RBC Capital
Leonid Timashev
$123 → $128MaintainsOutperformGet Alert
03/26/2024Buy Now72.95%Citigroup
David Hoang
$125 → $127MaintainsBuyGet Alert
03/26/2024Buy Now158.75%HC Wainwright & Co.
Raghuram Selvaraju
$180 → $190MaintainsBuyGet Alert
03/20/2024Buy Now145.13%HC Wainwright & Co.
Raghuram Selvaraju
 → $180ReiteratesBuy → BuyGet Alert
03/19/2024Buy Now47.08%Baird
Joel Beatty
 → $108Initiates → OutperformGet Alert
03/04/2024Buy Now145.13%HC Wainwright & Co.
Raghuram Selvaraju
 → $180ReiteratesBuy → BuyGet Alert
02/27/2024Buy Now47.08%Mizuho
Graig Suvannavejh
$112 → $108MaintainsBuyGet Alert
02/21/2024Buy Now70.23%Guggenheim
Yatin Suneja
$110 → $125MaintainsBuyGet Alert
02/21/2024Buy Now67.51%RBC Capital
Leonid Timashev
$126 → $123MaintainsOutperformGet Alert
02/21/2024Buy Now40.27%Cantor Fitzgerald
Charles Duncan
$108 → $103MaintainsOverweightGet Alert
02/20/2024Buy Now47.08%Cantor Fitzgerald
Charles Duncan
 → $108ReiteratesOverweight → OverweightGet Alert
02/16/2024Buy Now52.53%Mizuho
Graig Suvannavejh
$90 → $112MaintainsBuyGet Alert
02/06/2024Buy Now51.16%UBS
Ashwani Verma
 → $111Initiates → BuyGet Alert
01/25/2024Buy Now71.59%RBC Capital
Leonid Timashev
 → $126Initiates → OutperformGet Alert
01/22/2024Buy Now47.08%Cantor Fitzgerald
Charles Duncan
 → $108ReiteratesOverweight → OverweightGet Alert
01/16/2024Buy Now53.89%Piper Sandler
David Amsellem
$90 → $113MaintainsOverweightGet Alert
12/26/2023Buy Now145.13%HC Wainwright & Co.
Raghuram Selvaraju
 → $180ReiteratesBuy → BuyGet Alert
12/20/2023Buy Now47.08%Cantor Fitzgerald
Charles Duncan
 → $108ReiteratesOverweight → OverweightGet Alert
12/13/2023Buy Now70.23%Citigroup
David Hoang
 → $125Initiates → BuyGet Alert
12/12/2023Buy Now145.13%HC Wainwright & Co.
Raghuram Selvaraju
 → $180ReiteratesBuy → BuyGet Alert
11/07/2023Buy Now47.08%Cantor Fitzgerald
Charles Duncan
 → $108ReiteratesOverweight → OverweightGet Alert

FAQ

Q

What is the target price for Axsome Therapeutics (AXSM)?

A

The latest price target for Axsome Therapeutics (NASDAQ: AXSM) was reported by Mizuho on May 8, 2024. The analyst firm set a price target for $106.00 expecting AXSM to rise to within 12 months (a possible 44.36% upside). 43 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Axsome Therapeutics (AXSM)?

A

The latest analyst rating for Axsome Therapeutics (NASDAQ: AXSM) was provided by Mizuho, and Axsome Therapeutics maintained their buy rating.

Q

When was the last upgrade for Axsome Therapeutics (AXSM)?

A

The last upgrade for Axsome Therapeutics Inc happened on April 29, 2024 when Morgan Stanley raised their price target to $115. Morgan Stanley previously had an equal-weight for Axsome Therapeutics Inc.

Q

When was the last downgrade for Axsome Therapeutics (AXSM)?

A

The last downgrade for Axsome Therapeutics Inc happened on August 10, 2021 when Morgan Stanley changed their price target from $105 to $34 for Axsome Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Axsome Therapeutics (AXSM)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.

Q

Is the Analyst Rating Axsome Therapeutics (AXSM) correct?

A

While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a maintained with a price target of $109.00 to $106.00. The current price Axsome Therapeutics (AXSM) is trading at is $73.43, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch